Johnson & Johnson said Tuesday a second shot of its COVID-19 vaccine given about two months after the first increased its effectiveness to 94% in the United States against moderate to severe forms of the disease.
On Friday, an FDA advisory committee voted to recommend emergency authorization of additional Pfizer shots for Americans 65 and older and those at high risk of severe illness, but voted to recommend against broader approval, saying they want to see more data.
The Phase III two-dose trial of up to 30,000 participants tested the effectiveness of a second dose given 56 days after the first in adults 18 and older. The study had a short follow-up period of around 36 days, but found that a second dose was well tolerated, the company said. J&J said there was no evidence of reduced effectiveness over the study's duration from March to late July - a period that included the impact of the Delta variant.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
J&J says second shot boosts protection for moderate-severe Covid-19 to 94 percentThe company has now 'generated evidence that a booster shot further increases protection against Covid-19,' J&J’s chief scientific officer said Tuesday.
Read more »
Long Covid Affecting One Third Of People After Covid-19 Coronavirus Infection, CDC MMWR Study FindsSymptom rates were higher among females, Black people, and those 40 years and older or with pre-existing conditions.
Read more »
Covid-19: NI records five Covid-linked deaths, 889 casesThe total number of deaths linked to coronavirus in NI since the start of the pandemic is 2,504
Read more »
Covid-19 Vaccinations Boost the Global Economy, but May Not Cure It AloneCovid-19 vaccines are seen by governments as vital to boosting economic growth, but it isn’t clear that higher vaccination rates alone will do the trick
Read more »
U.S. and EU struggle with the same question: How to maximize COVID-19 vaccinationsDespite apparently divergent strategies, officials in both the U.S. and the EU are struggling with the same question: how to boost vaccination rates to the max and end a pandemic that has repeatedly thwarted efforts to control it.
Read more »